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http://dx.doi.org/10.1016/j.ccr.2012.12.019SUMMARYClear cell sarcoma (CCS) of tendons and aponeuroses is a deadly soft-tissue malignancy resembling mela-
noma, with a predilection for young adults. EWS-ATF1, the fusion product of a balanced chromosomal trans-
location between chromosomes 22 and 12, is considered the definitional feature of the tumor. Conditional
expression of the EWS-ATF1 human cDNA in the mouse generates CCS-like tumors with 100% penetrance.
Tumors, developed through varied means of initiating expression of the fusion oncogene, model human CCS
morphologically, immunohistochemically, and by genome-wide expression profiling. We also demonstrate
that although fusion oncogene expression in later stages of differentiation can transform mesenchymal
progenitor cells and generate tumors resembling CCS generally, expression in cells retaining stem cell
markers permits the full melanoma-related phenotype.INTRODUCTION
Clear cell sarcoma (CCS) is a soft-tissue neoplasm classically
arising in the extremities of young adults near tendons and
aponeuroses. Despite their often small size, these tumors
have high rates of recurrence and metastasis following stan-
dard local therapy, portending a poor general prognosis.
CCS was first identified in 1965 and then termed ‘‘malignant
melanoma of the soft parts’’ because of its histologic appear-
ance fitting with metastatic melanoma (Enzinger, 1965). In
addition, CCS was later found to demonstrate melanocytic
differentiation markers, including immunohistochemical posi-
tivity for M-MITF, S100B, MelanA, and HMB45 (Granter et al.,
2001; Hocar et al., 2012). Until recently, the only means of
differentiating CCS from the soft-tissue metastasis of a distantSignificance
CCS, a rare soft tissue malignancy typically arising in the e
EWS-ATF1, a fusion oncogene resulting from a t(12;22) chro
expression of the human EWS-ATF1 cDNA in the mouse dem
a number of cell types can be rendered tumorigenic via exp
appear to enable the full melanoma-related phenotype. Th
expression profile of CCS and explains the range of human
The mouse model should provide a robust platform for in
effective therapies for CCS.
Cmelanoma was its clinical history (i.e., confirmed absence of
any cutaneous melanomas).
In the last decade, recognition of the characteristic t(12;22)
(q13;q12) chromosomal translocation and its resultant fusion
oncogene EWSR1-ATF1 (EWS-ATF1) has provided a means of
defining CCS and distinguishing it from melanoma (Antonescu
et al., 2002). Traditional cytogenetics, fluorescent in situ hybrid-
ization (FISH), and RT-PCR have all proven to be diagnostic tools
capable of identifying this defining molecular feature of CCS
(Wang et al., 2009). The type 1 fusion of EWS-ATF1, which
includes exons one through eight of EWSR1 and exons four
through seven of ATF1, is the most common variant of the
described translocation products (Wang et al., 2009).
The EWS-ATF1 fusion protein contains the amino-terminal
transcriptional activation domain of the EWSR1 protein joinedxtremities of young adults, closely resembles melanoma.
mosomal translocation, defines the neoplasm. Conditional
onstrates its profound transformational impact. Although
ression of the fusion oncogene, the undifferentiated cells
is model deciphers part of the enigma of the melanoma
tumors derived from this powerful translocation product.
terrogating molecular mechanisms and developing more
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Figure 1. Conditional Expression of the
Human Clear Cell Sarcoma Fusion Onco-
gene in the Mouse
(A) Schematic showing the cDNA of the type I
variant of EWS-ATF1 isolated from a human tumor
and cloned into a vector designed for targeting into
the mouse Rosa26 locus. neo-R, neomycin resis-
tance cassette; polyA, polyadenylation stop se-
quence; IRES, internal ribosome entry site; eGFP,
enhanced green fluorescent protein. Cre-medi-
ated recombination excises the stop sequence
and initiates expression of the fusion oncogene
and eGFP.
(B) Embryonic day 14.5 fibroblasts isolated from
Rosa26EA1 heterozygous mice were exposed to
TAT-Cre protein or vehicle control, and images
were collected 24 hr later. The left two panels show
light images of fibroblasts, whereas the right two
panels show the GFP fluorescence. All scale bars
are 50 mm in length.
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scription factor 1 (ATF1). In the fusion protein, the EWSR1 activa-
tion domain replaces a protein kinase A phosphoacceptor site
that renders endogenous ATF1 activity dependent on the pres-
ence of cyclic adenosine monophosphate (Fujimura et al.,
2001). As a consequence, EWS-ATF1 is thought to be a constitu-
tive activator of ATF1-regulated genes. A small minority of CCS
cases harbor a t(2;22) (q32;q12) translocation and the alternate
CREB1 fusion partner replacing ATF1, with which CREB1 shares
binding of an identical consensus sequence (Wang et al., 2009).
The cell, or cells, of origin for CCS are not known. Traditionally,
CCS tumors were characteristically identified near the tendons
and aponeuroses of young adults but have also recently been
identified in the gastrointestinal tract (Covinsky et al., 2005;
D’Amico et al., 2012; Lyle et al., 2008) and dermis (Falconieri
et al., 2012; Hantschke et al., 2010). The expression of melano-
cyte-specific markers in CCS tumors has been variably attrib-
uted to the effects of the cell of origin or the effects of aberrant
M-Mitf expression, shown to be driven by EWS-ATF1 in CCS
cell lines (Davis et al., 2006). Using EWS-ATF1 as a diagnostic
marker led to the identification of CCSs that do not express
melanocytic markers. Further, some histologically distinct
neoplasms have also been associatedwith this fusion oncogene,
including angiomatoid fibrous histiocytoma (Somers et al., 2005)
and hyalinizing clear cell carcinoma of the salivary gland (Anto-
nescu et al., 2011). The latter tumors do not express M-Mitf or
other melanocytic markers.
To investigate the role that EWS-ATF1 plays in clear cell sarco-
magenesis and in tumorigenesis more broadly, we developed
a mouse model that expresses the human EWS-ATF1 fusion
oncogene complementary DNA (cDNA) in a conditional fashion.216 Cancer Cell 23, 215–227, February 11, 2013 ª2013 Elsevier Inc.RESULTS
Generation of a Targeted Mouse
Line Conditionally Expressing the
EWS-ATF1 Oncogene
To generate the EWS-ATF1 cDNA, total
RNA was isolated from human CCStumors, reverse transcribed, and screened by PCR to identify
a type 1 EWS-ATF1 fusion product. The integrity of the EWS-
ATF1 cDNA was confirmed by DNA sequencing. The EWS-
ATF1 cDNA was targeted to the ubiquitously expressed
Rosa26 locus (Mao et al., 1999). Linked to the EWS-ATF1
cDNA via an internal ribosomal entry site (IRES) was the
sequence encoding an enhanced green fluorescent protein
(eGFP). To prevent transcription of the fusion gene and eGFP
from the Rosa26 promoter, a neomycin resistance cassette
and poly-adenylation stop signal flanked by loxP sites was in-
serted between the promoter and the EWS-ATF1-IRES-eGFP
sequence (Figure 1A). In the absence of Cre, neither the fusion
gene product nor eGFP should be expressed. Temporal, spatial,
and tissue-specific control of Cre presence is possible through
a variety of techniques for its genetic or protein delivery. Mouse
embryonic stem cells confirmed to bear the targeted allele were
injected into blastocysts to generate chimeras that were then
bred to generate progeny with a germline-transmissible condi-
tional allele of EWS-ATF1 (designated Rosa26EA1).
To confirm inducibility of theEWS-ATF1 fusion gene and eGFP
by Cre, embryonic fibroblasts were isolated from E14.5 mouse
embryos heterozygous for the Rosa26EA1 allele and exposed in
culture to purified TAT-Cre protein or vehicle buffer control.
TAT-Cre is an engineered Cre protein containing a short peptide
sequence derived from the human immunodeficiency virus that
mediates efficient endocytic uptake and nuclear localization of
the protein (Joshi et al., 2002). Recombination efficiency
in vitro exceeds 95% as reported previously (Haldar et al.,
2009). Without exposure to TAT-Cre, mouse embryonic fibro-
blasts heterozygous for Rosa26EA1 demonstrated no green fluo-
rescence. Twenty-four hours after exposure to TAT-Cre (5 mM),
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fluorescing cells increased thereafter. The expression of other
sarcoma fusion oncogenes from the Rosa26 locus has proven
lethal for mouse embryonic fibroblasts (Haldar et al., 2007).
Surprisingly, EWS-ATF1-expressing fibroblasts survived beyond
the expected crisis and senescence of control fibroblasts that
carried the Rosa26EA1 allele but were exposed to vehicle rather
than TAT-Cre. Expression of EWS-ATF1 remained strong in the
embryonic fibroblasts activated by TAT-Cre, even following
long-term passage (data not shown).
Generation of Tumors by In Vivo Exposure to TAT-Cre
Because expression of EWS-ATF1 was so well tolerated in vitro,
we investigated whether the Rosa26EA1 allele might be activated
in vivo first by injecting TAT-Cre into mice heterozygous for the
Rosa26YFP allele. Mice receiving TAT-Cre show YFP expression
within 24 hr of injection (Figure S1A available online). To look at
this on a cellular level, mice heterozygous for Rosa26mTmG
reporter allele (Muzumdar et al., 2007) were also injected
with TAT-Cre. All cells in mice bearing the Rosa26mTmG allele
express membrane-bound Tomato fluorescent protein prior to
recombination with Cre but express a membrane-bound GFP
after Cre-mediated excision of the mTomato coding sequence.
A single subdermal injection of TAT-Cre resulted in dense GFP
expression in the surrounding tissue (Figure S1B).
To determine the sufficiency of the EWS-AFT1 fusion gene to
drive clear cell sarcomagenesis in vivo, we injected TAT-Cre
protein into the anterolateral soft tissues abutting the tibia and
in the distal forelimbs of mice heterozygous for the Rosa26EA1
allele. EWS-ATF1 transcripts were detectable by RT-PCR from
tissues harvested within 24 hr of the TAT-Cre injection (Fig-
ure S1C). Every injection of TAT-Cre yielded a tumor (Figure 2A),
tightly localized to the injection site. Control mice, including both
uninjected littermates and littermates injectedwith saline and fol-
lowed for 15 months, never formed tumors. All mouse tumors
derived from the TAT-Cre-activated Rosa26EA1 allele demon-
strated eGFP fluorescence (Figure 2A).
Noting an extremely brief latency to tumorigenesis, the ability
to form tumors in a broad array of tissue locations, and the histo-
logical appearance of poly-clonality among the first rounds of
TAT-Cre-induced tumors, we investigated whether the rapid
growth of large tumors might result primarily from a large initial
population of induced EWS-ATF1-expressing cells. To address
this question, we injected limbs of mice heterozygous for the
Rosa26EA1 allele with different concentrations of TAT-Cre and
found that the latency to tumor formation correlated with the
concentration of TAT-Cre administered (Figure 2B). Injecting
100 mM of TAT-Cre resulted in visible tumors as quickly as
3 weeks postinjection, with 100% penetrance per injection site
by 6weeks. TAT-Cre at 2 mMstill produced tumorswith full pene-
trance but required a longer latency with visible tumors observed
after a period of 6 to 9 months. Although TAT-Cre concentration
impacted latency to development of a visible tumor, it did not
impact the observed rate of tumor growth following visible
detection of any specific tumor. Tumors appearing early from
concentrated TAT-Cre or after a longer latency from diluted
TAT-Cre still grew at a similarly rapid rate after detection.
The tumors that formed following TAT-Cre injection into mice
heterozygous for the Rosa26EA1 allele recapitulated humanCCCS molecularly, with expression of the fusion oncogene and
melanocytic markers M-Mitf and Tyrosinase (Figure 2C). Mouse
tumors also matched human tumor histomorphology and immu-
nohistochemical profile. In hematoxylin and eosin (H&E)-stained
sections, the majority of murine tumors demonstrated nuclear
features typical of primitive cell types, with prominent open chro-
matin patterns as well as abundant clear cytoplasm (the feature
for which the tumor is named) (Figure 2D). Although some tumors
had a pseudoencapsulated, pushing border with surrounding
tissues, others demonstrated clear infiltration into adjacent
tissue planes. A minority subset of tumors (20%) demonstrated
spindle cell morphology, also observed in some human CCS
cases (Figure 2D). Consistent with human CCS, the tumors
demonstrated immunohistochemical positivity for melanocytic
markers (M-MITF and S100B) and lacked staining for cytokera-
tins (Figure 2E).
Unbiased Expression of EWS-ATF1 Also Results in
Tumorigenesis, Preferentially in Mesenchyme
Because tumors rapidly invaded surrounding tissues, dissec-
tions of the limbs did not clearly indicate from which tissues
they arose. In a search for tissues incompatible with transforma-
tion, TAT-Cre was injected into subcutaneous adipose, dorsal
paw peritendinous, periosteal, intramuscular, and mammary
fat pad tissue compartments in mice between 3 weeks and
6 months of age. The latency to tumor appearance varied with
age and injection site, but every injection in each of these tissue
locations yielded completely penetrant tumorigenesis (Table
S1). Each of these locations bears some cells of mesenchymal
character, but whether these or neighboring cells actually gave
rise to tumors remained unclear.
In order to broaden exposure to EWS-ATF1 fusion protein
across multiple cell types and developmental periods, we next
utilized Rosa26CreER to express Cre sporadically, in random
cell types. Although efficient CreER-mediated recombination
requires the presence of tamoxifen, a very low level of CreER-
mediated recombination is observed even in the absence of
tamoxifen (Haldar et al., 2009). Breeding mice bearing the
Rosa26CreER allele to mice bearing the Rosa26EA1 allele resulted
in smaller litters than breeding Rosa26EA1mice alone, fitting with
the previously described early embryonic leakiness of this CreER
and suggesting some developmental toxicity of early expression
of EWS-ATF1 (Figure 3A).
Among the Rosa26CreER/EA1mice that survive embryogenesis,
administration of tamoxifen prior to 3 weeks of age results in
stunted growth (Figure 3B) and death by 12weeks of agewithout
detectible tumor formation. Rosa26CreER/EA1 mice receiving
tamoxifen after 3 weeks of age form more tumors than those
receiving no tamoxifen, but both of these groups demonstrate
complete penetrance of tumor formation by 12 weeks of age
(Figure 3C). The tumors arising in Rosa26CreER/EA1 mice were
histologically similar to the murine TAT-Cre-induced tumors
and human clear cell sarcoma (Figure 3D). Whether or not
enhanced by later tamoxifen administration, tumors arose
most often in the extremities, rib cage, and facial tissues of the
Rosa26CreER/EA1 mice but were also less frequently found in
the dermis, liver, and bone (Table S2). As following TAT-Cre
induction, the preponderance of tumors arose in mesenchymal
tissue compartments. A variety of mouse cells are permissiveancer Cell 23, 215–227, February 11, 2013 ª2013 Elsevier Inc. 217
Figure 2. TAT-Cre-Initiated Expression of EWS-ATF1 In Vivo Leads to Tumorigenesis
(A) Radiographs of limbs of Rosa26EA1 heterozygous mice without (top) or with (bottom) injection of TAT-Cre (left two columns). Necroscopy light and GFP
fluorescence photo of Rosa26EA1 limb without injection (top) or of tumor extracted from the TAT-Cre-injected Rosa26EA1 (bottom) (right two columns). Arrows
point to individual tumors.
(B) Latency to visible tumor formation for Rosa26EA1 mice injected with 100, 10, and 2 mM solutions of TAT-Cre.
(C) RT-PCR analysis of the indicated mRNAs from uninjected control tissues and TAT-Cre-induced tumors.
(D) Representative histology of TAT-Cre-induced tumors with H&E stain showing a multinodular tumor at low power (left), cells marked by round shape, clear
cytoplasm and an open chromatin pattern at higher power (middle), and a tumor having a more spindled cell morphology (right).
(E) Immunohistochemical stains for M-MITF (left), S100B (middle), and cytokeratin 5 (right). All black scale bars are 100 mm in length, and the white bar is 500 mm.
See also Figure S1 and Table S1.
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Figure 3. Early Expression of EWS-ATF1 in
the Broad Rosa26CreER-Lineage Renders
Stunted Growth, but Later Expression
Drives Tumorigenesis
(A) The number of pups per litter of mice hetero-
zygous for the Rosa26CreER allele crossed with
mice homozygous for the Rosa26EA1 allele com-
pared to that of Rosa26EA1/EA1 backcrossed
controls.
(B) Photograph of a 7-weeks-old male
Rosa26EA1/CreER mouse injected with tamoxifen at
10 days (white arrow) and two uninjected female
littermates of the same genotype.
(C) Chart of the number of tumors per mouse at
12 weeks age among Rosa26EA1/CreER mice in-
jected with tamoxifen after 3 weeks (late, n = 4),
before 3 weeks (early, n = 3), or not at all (n = 5).
Error bars denote standard deviation, t test
p < 0.05.
(D) H&E-stained histopathology demonstrating
the classic clear cell morphology apparent in a
Rosa26CreER-initiated tumor after late injection of
tamoxifen. Scale bar is 20 mm in length.
See also Table S2.
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tumor tissue locations observed in molecularly defined human
cases of CCS but preferentially arising in mesenchyme.
EWS-ATF1 Drives an Expression Signature of
Transformation
Because the brief latency to tumorigenesis in both models sug-
gested a powerful role for EWS-ATF1 in driving transformation,
we sought to define the expression signature shared by tumors
from both means of inducing EWS-ATF1 expression. To this
end, we harvested tumors from each cohort as well as from
control mesenchymal tissue, consisting of a portion of the
thoracic cage, including cartilage, bone, skeletal muscle, and
connective tissue, isolated total RNA from each, and performed
Illumina sequencing. The samples generated an average of
24.4 ± 3.1 million reads, which aligned to 16,840 ± 778 genes at
greater than or equal to 0.1 reads per kilobase permillion (RPKM).
Clustering analysis demonstrated highly similar expres-
sion profiles among tumors induced by either TAT-Cre or
Rosa26CreER, both distinct from control tissues. An unsupervised
hierarchical clustering of the samples according to the 200 most
differentially expressed genes is shown in Figure 4A (gene lists in
Tables S3, S4, and S5). DAVID analysis of the most significantly
upregulated genes in the mouse tumors compared to control
tissues highlighted several informative KEGG pathways,
including cell-cycle control, cancer, p53, and extracellular matrix
pathways (Huang da et al., 2009a, 2009b) (Figure 4B). These
data provide insight into the transforming power of EWS-ATF1,
with consistent alterations in gene expression profiling among
different methods of activation.
Embryonic Expression of EWS-ATF1 in Mesenchymal
Tissues and Predecessors Causes Lethality
Although experiments with TAT-Cre injections and Rosa26CreER-
initiated EWS-ATF1 expression suggested that a variety of cellCtypes appear to support a program of transformation, they also
suggested that the preferred clear cell sarcomagenesis tissue
of origin is mesenchyme. As postnatal mesenchymal tissues
derive from both neural crest and mesodermal origins, we inves-
tigated the identity of potential cells of origin by breeding mice
bearing the Rosa26EA1 allele to mice bearing Cre expressed
from promoters specific to these lineages. With regard to neural
crest, mice bearing the Rosa26EA1 allele and Wnt1-Cre (Danie-
lian et al., 1998) did not complete embryogenesis. Conditional
EWS-ATF1 activated by Pax3-Cre (Engleka et al., 2005), Pax7-
Cre (Keller et al., 2004b), Tie2-Cre (Kisanuki et al., 2001), or
Prx1-Cre (Durland et al., 2008; Logan et al., 2002), all expressed
in mesoderm, also resulted in embryonic lethality.
At E13.5, the Prx1-Cre lineage demonstrated GFP fluores-
cence in Prx1-Cre;Rosa26EA1 mouse embryos, indicating
expression of eGFP from the IRES on the EWS-ATF1 transcript
(Figure 5A). As late as E14.5 Prx1-Cre;Rosa26EA1 mouse
embryos remained viable but demonstrated severe limb
deformities (Figure 5A). It suggests that EWS-ATF1 was toxic
to these cells.
Pax7-Cre; Rosa26EA1 did not produce live progeny, but
embryos were retrieved as late as E18.5. These embryos
showed severe craniofacial deformation with no visible eGFP,
which suggests that the lineage cannot survive expression of
EWS-ATF1 (Figure S2A).
Mice bearing the Rosa26EA1 allele and Myf5-Cre, which acti-
vated the fusion gene expression in myoblasts (Haldar et al.,
2007), did not form tumors but demonstrated another phenotype
in which EWS-ATF1 was also apparently toxic to cells. These
mice survived to birth and lived to approximately 3 months of
age but were very small in size and severely myopathic, with
eGFP expression detectable in the remaining muscle fibers
(Figures S2B and S2C).
These data demonstrate that even though the expression of
EWS-ATF1 is tolerated better than the expression of otherancer Cell 23, 215–227, February 11, 2013 ª2013 Elsevier Inc. 219
Figure 4. The Expression Signature ofEWS-
ATF1-Driven Tumors
(A) Heat map depicting the 200 most significantly
(p < 0.001) differentially expressed genes between
TAT-Cre- or Rosa26CreER-initiated tumor and
control tissue, as assessed by transcriptome
sequencing.
(B) DAVID analysis of the most upregulated genes
in tumors highlights Kegg pathways known to be
involved in transformation.
See also Tables S3, S4, and S5.
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blasts in vitro andmany tissues in vivo when induced after wean-
ing, it is of significant toxicity in specific tissue settings during
development.
EWS-ATF1 Expression in Postnatal Mesenchymal
Progenitors Generates Two CCS Tumor Types
Noting that early tamoxifen administration in Rosa26CreER/EA1
mice did not result in tumorigenesis but later administration
did (Figure 3), we hypothesized that the toxicity prompted in
the mesenchymal tissues embryonically might be avoided at
later stages of development. In order to test this hypothesis,
we bred mice bearing the Rosa26EA1 allele to mice bearing
either Pax7CreERT2 (Murphy et al., 2011) or Prx1-CreERT2 (Has-
son et al., 2007), then administered tamoxifen after three weeks
of age. By 12 months posttamoxifen, myopathy consistently
developed in the Pax7CreERT2;;Rosa26EA1 mice, but no tumors
were observed (Figures S2D and S2E). The absence of tumor
formation argues against muscle satellite cells being a potential
cell of origin for EWS-ATF1-induced tumors. In the embryo,
Prx1-Cre is widely expressed in the mesenchyme of the220 Cancer Cell 23, 215–227, February 11, 2013 ª2013 Elsevier Inc.developing mammalian limb and head
(Durland et al., 2008), whereas Prx1-
CreERT2 expression is reported to be
restricted postnatally to a smaller
progenitor cell population in the same
anatomic regions, still capable of osteo-
chondrogenic differentiation (Kawanami
et al., 2009).
Prx1-CreERT2;Rosa26EA1 mice devel-
oped tumors (Figure 5B) by 8 weeks
posttamoxifen injection with 100% pene-
trance. Most of these tumors developed
in the extremities and head, consistent
with the expected anatomic distribution
of Prx1 postnatal expression. The tumors
showed GFP fluorescence marking
expression of the EWS-ATF1-IRES-
eGFP transcript (Figure 5B). The Prx1-
CreERT2-induced tumors appeared to
arise from the periosteal/perichondrial
layer as well as from within the muscula-
ture as judged by gross microscopy
and histology (Figures 5B and 5C). The
tumors induced in the Prx1 lineage
demonstrated either the clear cell mor-phology with lightly stained eosinophilic cytoplasm or spindle
cell morphology, both closely resembling tumors induced by
TAT-Cre.
Notably, some tumors induced by Prx1-CreERT2 expressed
M-MITF, but others did not (Figure 5D). CCS in humans often
but not always expresses M-MITF (Granter et al., 2001). Thus,
it appears that induction of EWS-ATF1 expression with Prx1-
CreERT2 generated both subtypes of CCS.
EWS-ATF1 Expression in Postnatal Mesenchymal Stem
Cells Generates CCSs with a More Consistent
Phenotype
In order to interrogate possible cells of origin in the undifferenti-
ated progenitor cell population that precedes Prx1 expression
postnatally, we bred mice bearing the Rosa26EA1 allele to mice
bearing Bmi1CreERT2 (Sangiorgi and Capecchi, 2008). Bmi1 is
a general marker for stem cells and has been demonstrated to
label intestinal, neural, epidermal, and hematopoietic stem cells
(Claudinot et al., 2005; Leung et al., 2004; Park et al., 2003; San-
giorgi and Capecchi, 2008). A single peritoneal injection of
tamoxifen into Bmi1CreERT2;Rosa26EA1 mice after 3 weeks of
Figure 5. EWS-ATF1Drives Apoptosis in the
Embryonic Prx1-Lineage and Tumorigen-
esis in the Postweaning Prx1 Lineage
(A) GFP fluorescence image of Prx1-Cre;
Rosa26EA1 embryos at embryonic day 13.5 (far
left). Prx1-Cre;Rosa26EA1 at E14.5 (top middle),
compared to littermate controls lacking Prx1-Cre
(bottom middle); the limbs of mutant and control
are enlarged to show difference in size (outlined in
right panels).
(B) Radiograph of a Prx1-CreERT2;Rosa26EA1
mouse 8 weeks after a single tamoxifen injection
at 4 weeks of age (left), gross necropsy
photos with halogen light (middle) or GFP fluo-
rescence (right) of Prx1-CreERT2;Rosa26EA1 limb
8 weeks posttamoxifen injection (arrows point to
tumors).
(C) H&E-stained histopathology of Prx1-CreERT2;
Rosa26EA1 tumor immediately adjacent to bone
(upper) and tumor exhibiting classic clear cell
sarcoma morphology (lower).
(D) Immunohistochemistry for M-MITF on Prx1-
CreERT2;Rosa26EA1-derived tumors. Scale bars
are 100 mm in length.
See also Figure S2.
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developed tumors in the deeper mesenchymal tissues of
the limb and trunk (Figure 6A). Some tumors formed com-
pletely within and surrounded by muscle (Figure 6B), similar to
a subset of the Prx1-lineage tumors. A larger portion formed
adjacent to bone, arising from the periosteum/perichondrium,
also similar to several of the Prx1-lineage tumors (Figure 6B).
The Bmi1-lineage tumors consistently matched the clear cell
morphology and immunohistochemical profile of human CCS
tumors, uniformly demonstrating M-MITF and S100B (Figures
6B and 6C).
Prior reports have suggested a role for Bmi1 in mesen-
chymal stem cells based on depletion of the pool of osteo-
chondroprogenitors in mice bearing homozygous disruption
of Bmi1 (Zhang et al., 2010). To follow up these studies
and more fully characterize the Bmi1 lineage in mesen-Cancer Cell 23, 215–227,chyme, mice bearing Bmi1CreERT2
were crossed to a robust reporter
mouse expressing tdTomato condition-
ally from the Rosa26 locus. Bmi1CreER;
Rosa26tdTomato mice were injected with
a single dose of tamoxifen at 6 weeks
of age, and their limb tissues were har-
vested 1, 2, and 9 months postinjection
for analysis.
We analyzed the early Bmi1 lineage
focused on the mesenchymal progenitor
population within the bone marrow and
endosteum. Nestin has recently been
shown to be an accurate marker of the
multipotent mesenchymal stem cell
subpopulation in this location, whereas
no specific markers are agreed upon in
the periosteum (Me´ndez-Ferrer et al.,2010). Colabeling experiments on tissue sections revealed
the colocalization of the early Bmi1 lineage marker to the
Nestin-expressing cells, both at the endosteal surface in the
bone marrow and in periosteum (Figure 6D), indicating that
Bmi1 is indeed expressed in this mesenchymal stem cell
population. Lineage tracing experiments from tissues har-
vested 60 days and 9 months following tamoxifen administra-
tion revealed that Bmi1-expressing cells contribute to both
osteoblast and chondrocyte lineages (Figure 6E), further
affirming Bmi1 as a marker of very early, stem-like cells in
mesenchyme. The previously described Prx1-CreERT2-
defined lineage marks a similar but smaller population of these
differentiated mesenchymal cells (Kawanami et al., 2009).
Using an antibody against Prx1 to locate cells actively ex-
pressing the marker, we found a portion but not all of the cells
in the Bmi1CreER;Rosa26tdTomato lineage expressed Prx1,February 11, 2013 ª2013 Elsevier Inc. 221
Figure 6. The Bmi1 Lineage, Including
Mesenchymal Stem Cells, Enables More
Consistent Development of Clear Cell
Sarcomas with Melanocytic Features
(A) Living image of Bmi1CreERT2;Rosa26EA1 mouse
with black arrows indicating tumor formation (far
left), radiograph (left), necropsy photo (right), and
GFP fluorescence (far right) image of tumor formed
in the chest wall (yellow arrow showing location of
the tumor).
(B) H&E-stained histopathology of Bmi1CreERT2-
initiated tumors, including both intramuscular (left)
and periosteal/perichondrial (right) tumors.
(C) Immunohistochemistry of Bmi1CreERT2-initi-
ated tumors stained for M-MITF (left) and S100B
(right).
(D) Immunofluorescence for Nestin (green)
and Bmi1CreERT2-induced expression of
tdTomato (red) in Bmi1CreERT2; Rosa26tdTomato
mice 30 days after injection of tamoxifen shown
in the bone marrow BM (left) and periosteum P
(right).
(E) Bmi1-lineage tracing from Bmi1CreERT2;
Rosa26tdTomato mouse at 60 days posttamoxifen
demonstrates tdTomato fluorescence (red) in
osteoblasts and chondrocytes.
(F) Immunofluorescence against Prx1 (green)
and Bmi1 lineage defined by tdTomato (red) in
Bmi1CreERT2;Rosa26tdTomato mice 30 days post-
tamoxifen injection.
(G) Immunofluorescence against CD31 (green)
and tdTomato Bmi1-lineage cells (red) at 60 days
posttamoxifen All scale bars are 100 mm in length.
See also Figure S3.
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express Prx1 (Figure 6F). Lineage tracing with Prx1-CreERT2
mice and immunofluorescence against Nestin confirmed
that a subset of Prx1-lineage cells still express Nestin as
well (Figure S3A).
Although mesenchymal stem cell and progenitor populations
within and adjacent to the bone explain the location of some
tumors arising in both the Bmi1 and Prx1 lineages, other
tumors in both groups arose within the muscle compart-
ments. Because it has previously been demonstrated that
Bmi1 is expressed in Pax7-positive satellite cells within muscle
(Robson et al., 2011), it is possible that the intramuscular
Bmi1-lineage tumors could arise from this cell population.
However, we already discussed that Pax7CreERT2; Rosa26EA1
do not form tumors, arguing against the possibility that222 Cancer Cell 23, 215–227, February 11, 2013 ª2013 Elsevier Inc.satellite cells provide a potential cell of
origin for CCS (Figures S2D and S2E).
Further analysis of the Bmi1 lineage
within the muscle compartments identi-
fied not only satellite cells but also CD31-
expressing endothelial cells (Figure 6G).
Lineage tracing with Prx1-CreERT2 mice
identified CD31+ endothelial cells within
its lineage as well (Figure S3B). A perivas-
cular population of cells that has ex-
pressed both Bmi1 and Prx1, perhaps atdifferent stages of differentiation, may serve as the originating
cells of the CCS tumors that appear within the muscle compart-
ments in these two groups.
Murine CCS Tumors Fit the Human CCS Expression
Profile; Variations Appear to Reflect Different Cells of
Origin
In order to determine the impact of these varied potential
cells of origin on the resultant tumors, we performed RNA
sequencing on a panel of mouse CCS tumors, induced by
TAT-Cre, Rosa26CreER, Bmi1CreERT2, and Prx1-CreERT2. We
simultaneously sequenced RNA from mouse synovial sarcomas
and osteosarcomas, as well as control mesenchymal tissue.
Using Spearman correlation as the distance metric and an
average linkage, CCS from all induction methods clustered
Figure 7. Tumors Derived from EWS-ATF1
Expression in Different Cells of Origin
Cluster Together According to Expression
Profile and Fit Human Clear Cell Sarcoma
Profiles
(A) Unsupervised hierarchical clustering of mouse
samples by sequencing-defined transcriptional
profiling, osteosarcomas (triangle), synovial
sarcomas (diamond), EWS-ATF1-driven tumors by
TAT-Cre (red circles), Rosa26CreER (pink circles),
Bmi1CreERT2 (dark blue circles), and Prx1-CreERT2
(light blue circles) and control samples from chest-
wall mesenchymal tissues (cross).
(B) Unsupervised hierarchical clustering of human
tumors profiled by microarray and used to train the
supervised machine-learning module, solitary
fibrous tumor (triangle), myxoid liposarcoma
(square), melanoma (pentagon), leiomyosarcoma
(triangle), synovial sarcoma (diamond), and clear
cell sarcoma (circle). The mouse EWS-ATF1-
driven tumors are placed under the category
of human tumors they most identified with on
the supervised machine-learning module, TAT-
Cre (red circles), Rosa26CreER (pink circles),
Bmi1CreERT2 (dark blue circles), and Prx1-CreERT2
(light blue circles).
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sarcoma types (Figure 7A).
To test the extent of molecular similarity between human
CCS and the tumors induced by expression of EWS-ATF1 in
mice across the range of tissues of origin, we compared
mRNA sequencing expression analysis of mouse CCS tumors
to microarray-derived expression data from a panel of related
human tumors. A support vector machine (SVM), or supervised
machine learning, technique was created to predict the identity
of a tumor using a training platform built by human HEEBO mi-
croarray data from samples of CCS, melanoma (MEL), solitary
fibrous tumor (SFT), leiomyosarcoma (LMS), myxoid liposar-
coma (MLS), and synovial sarcoma (SS), all of which, except
CCS, were previously reported (Nielsen et al., 2002). We first
filtered the human data by mapping the HEEBO probes to
the mm9 mouse reference genome, retaining only the 12,246
probes whose alignments demonstrated at least 80%
homology across the probe length. The human expression
data across this subset of probes was used to train the linear
SVM model by creating CCS and non-CCS classes (n = 4
and 25, respectively). The normalized RPKM mouse data
were input into the SVM as read depths per probe and classi-
fied into one of the two classes. Twelve of 13 murine CCSCancer Cell 23, 215–227,tumors were predicted to be human
CCS, rather than one of the other tumor
types (Figure 7B). As a control, zero of
five RNA sequencing data sets from
wild-type mouse mesenchymal tissue
controls were identified as human CCS
when input into the same SVM. These
data confirm that mouse tumors derived
from conditional expression of EWS-
ATF1 resemble the expression profile ofhuman CCS more closely than the other soft-tissue tumors or
melanoma.
Notably, the one mouse CCS that did not cluster closely to the
human CCS SVM prediction was a Prx1-CreERT2-initiated
tumor that did not express M-Mitf. In contrast, another Prx1-
CreERT2-initiated tumor that expressed M-Mitf did cluster with
human clear cell sarcoma.
Further comparative analysis of the RNA-sequencing expres-
sion profiles of the two Prx1-lineage and the two Bmi1-lineage
tumors, both sets from the same anatomic locations, identified
a number of consistently differentially expressed genes. Three
of the top ten genes more highly expressed in Prx1-CreERT2;
Rosa26EA1were Crlf1, which is present in osteoblasts and chon-
drocytes, along with Saa1 and Saa2, which are upregulated in
differentiated compared to undifferentiated mesenchymal stem
cells (Clancy et al., 2003; Kovacevic et al., 2008).
To better evaluate the difference between the Bmi1CreERT2;
Rosa26EA1 and Prx1-CreERT2;Rosa26EA1 tumors, we performed
RT-PCR on a panel of additional samples. This revealed that
some Prx1-lineage tumors indeed expressed M-Mitf and Tyros-
inase but not all (Figure 8A). All Bmi1-lineage tumors expressed
thesemelanocytic markers. Interestingly, the Prx1-lineage tumor
that did not express Nestin also did not express M-Mitf orFebruary 11, 2013 ª2013 Elsevier Inc. 223
Figure 8. Tumors Arising from EWS-ATF1
Expression Initiated in the Prx1 or Bmi1
Lineages Differ by Expression Profile
(A) RT-PCR analysis of the indicated transcripts on
total RNA isolated from Bmi1- and Prx1-lineage
tumors (arrow points to the correct band).
(B) Working model of the impact of early differen-
tiation within multipotent mesenchymal progeni-
tors on the possibility of transdifferentiation to
express melanocytic markers upon clear cell
sarcomagenesis driven by EWS-ATF1.
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Modeling Clear Cell SarcomaTyrosinase. An additional Prx1-lineage tumor failed to express
Tyrosinase only. This may indicate that between the stem-like
state of Bmi1 expression and the progenitor state of Prx1
expression Nestin, M-Mitf, and Tyrosinase are epigentically
silenced (Figure 8B).
DISCUSSION
A few mouse genetic models of translocation-associated
sarcomas have been described over the last decade, including
models of alveolar rhabdomyosarcoma expressing PAX3-
FKHR (Keller et al., 2004a, 2004b; Keller and Capecchi, 2005),
myxoid liposarcoma expressing FUS-CHOP (Pe´rez-Losada
et al., 2000), and synovial sarcoma expressing SS18-SSX2
(Haldar et al., 2007, 2008, 2009). The last of these used means
of transcriptional control of the fusion oncogene similar to
those used in the current study, with expression in Cre/loxP
conditional fashion from theRosa26 locus. Themodel of synovial
sarcoma also demonstrated fully penetrant tumorigenesis when
initiated by Rosa26CreER or Myf5Cre (Haldar et al., 2009).224 Cancer Cell 23, 215–227, February 11, 2013 ª2013 Elsevier Inc.Comparison of the two models highlights
the brief latency to tumorigenesis fol-
lowing expression of EWS-ATF1 initiated
by Rosa26CreER. The synovial sarcoma
model develops tumors after a year,
rather than within 3 months. Further,
expression of SS18-SSX2 in most cells,
in vitro or in vivo, was toxic. The very rapid
onset of visible tumors in the mouse CCS
model relative to synovial sarcoma sug-
gest that fewer additional hits may be
required to foster progression of the
tumor. This may represent a fundamental
difference between the biology of the two
fusion oncogenes, as all other aspects of
the models are the same.
It has not escaped our notice that the
extreme oncogenicity of EWS-ATF1 in
mice contrasts with the rare incidence of
formally diagnosed CCS in humans. A
potential explanation for this discrepancy
is the possibility that EWS-ATF1 involve-
ment in human tumorigenesis remains
underappreciated. t(12;22) (q13;q12)
chromosomal translocation and resultant
fusion oncogenes are identified onlywhen pursued in clinical tumors. The widening range of tumors
recently found to bear EWS-ATF1, such as angiomatoid fibrous
histiocytoma and clear cell carcinoma of the salivary gland (An-
tonescu et al., 2011; Chen et al., 2011; Mangham et al., 2010;
Ren et al., 2009), suggests that more may yet be identified in
the near future. Second, the observed toxicity to embryonic
development in the mouse by the early expression of the
EWS-ATF1 fusion gene may greatly limit the acceptable time
frame for the formation of the required t(12;22) chromosomal
translocation in humans. Finally, not all balanced chromosomal
translocations arise with equal frequency, and the formation of
the t(12;22) translocation responsible for CCS may be the rate
limiting step for this malignancy.
Different cells of origin impacted features of the tumors
resulting from EWS-ATF1 expression. Tumors from both the
Bmi1 and Prx1 postnatal lineages developed in nearly identical
anatomic locations (in the muscle and from the periosteal
surface of bones) and fit the histologic appearance of
human CCS, but the Prx1-lineage tumors did not consistently
express the melanocytic markers M-Mitf and Tyrosinase. The
Cancer Cell
Modeling Clear Cell SarcomaM-Mitf-expressing Prx1-lineage tumors fit the general expres-
sion signature of human CCS. Those not expressing M-Mitf did
not. This observation may explain the fact that not all human
CCSs clearly express melanomamarkers. All four human tumors
used for expression profiling were typical M-Mitf-expressing
melanoma-like CCSs. Perhaps, the Prx1-induced mouse tumor
that did not express M-Mitf might have fit better with a broader
group of human CCSs.
Expression of Nestin has previously been reported in human
CCS cell lines (Dimas et al., 2008). All Bmi1-lineage tumors ex-
pressed Nestin and the melanocytic markers, whereas variable
Nestin expression in Prx1-lineage tumors predicted expression
of the melanocytic markers. Nestin has previously been proven
to be a marker of stemness in mesenchyme (Me´ndez-Ferrer
et al., 2010) and to overlap with the Bmi1 lineage and partly
with the Prx1 lineage. This evidence along with the colabeling
experiments showing Prx1 expression within the Bmi1 lineage
suggests that the differentiation steps betweenBmi1-expressing
cells and Prx1-expressing cells include a gradual loss of stem-
ness. The epigenetic state may render the melanocytic markers
unavailable for upregulation by ATF constitutive activation alone
(Figure 8B).
Many have argued in the past about the origin of the melano-
cytic features of human CCS, variably attributing them to either
cell of origin or transformation by EWS-ATF1, which also upregu-
lates M-Mitf. Although we have not ruled out the possibility that
melanocytes or their precursors might also offer sufficient cells
of origin, the tumors we have induced in mesenchyme actually
bolster both prior arguments. CCS transformation can enable
transdifferentiation that includes melanocytic markers but only
from certain cells of origin. Perhaps a cell’s reprogrammability,
even during aggressive transformation from expression of
a powerful fusion oncogene, remains at least partly checked
by its antecedent differentiation state.
This mouse model will enable additional dissection of the
ATF pathway’s impact on oncogenesis in vivo. Further, the
model is ideally suited to preclinical testing of targeted therapies
for this and other CCS pathways. Administration of TAT-Cre
produces visible tumors within a few weeks and avoids any
pleiotropic developmental effects from toxicity of the fusion
oncogene expressed across an entire tissue. These tumors are
well localized, offering a reasonable model for the study of
metastasis. Unlike delivery of Cre with a virus, a single molecule
of TAT-Cre cannot readily diffuse to a great distance or travel
through the blood stream to a distant site and induce recombina-
tion, as at least two molecules of the TAT-Cre protein must
enter any given cell to catalyze the recombination event (Joshi
et al., 2002).
Because of the low frequency of sarcomas, the most critically
scarce resource for developing more effective therapeutic strat-
egies for thesemalignancies is patients themselves. It is not easy
to assemble sufficient numbers of patients for carrying out
subtype-specific sarcoma clinical trials. Therapeutic strategies
must be optimized and prioritized in the preclinical arena before
advancing to clinical trial. Authenticated mouse models could
serve this purpose. Genomic sequencing and profiling has vastly
increased the ability to test the authenticity of a mouse model’s
recapitulation of human malignancy. Once established as an
excellent facsimile to the human cancer, a mouse model canCbe used not only to interrogate cancer mechanisms and identify
pertinent therapeutic targets but also as a platform for assess-
ment of drug efficacy. Successful candidate therapeutic strate-
gies could be thenmoved to human trials with greater assurance
of success.
In summary, we have shown that the oncogenic fusion protein
that characterizes CCS is sufficient to initiate CCS-like tumors in
mice that recapitulate human CCS in terms of cell morphology,
immunohistochemistry, and genome-wide expression. This
fusion gene generates two distinguishable tumor types in mice
that also reflect similar variance in morphology and tissue distri-
bution seen in humans (i.e., principally falling in two classes:
those that resemble melanomas because of the expression of
M-Mitf and its target genes and those that do not). The apparent
difference in cells of origin of these two potential subclasses
described herein with mice may provide an explanation of why
human CCS commonly, but inconsistently, displays the classical
melanocytic features.
EXPERIMENTAL PROCEDURES
Targeted Mouse Line Production
Human EWS-ATF1 cDNA was obtained by RT-PCR of total RNA from eight
histologically and immunohistochemically confirmed clear cell sarcoma
tumors. The total RNA was obtained as deidentified patient sample through
an approved University of Utah Institutional Review Board Protocol. PCR
was used to identify tumors that contained the type 1 EWS-ATF1 fusion
gene. After screening, the cDNA sample was used to amplify the entire fusion
oncogene. The cDNA clone was subcloned into the Rosa26UA plasmid using
AscI and Fse1 Sites. This plasmid contained the Loxp-pgk-Neo-tPA-Loxp-
AscI-FheI-IRES-EGFP within the Rosa26 homology arms, and the final target-
ing construct contained Loxp-pgk-Neo-tPA-Loxp-EWS-ATF1-IRES-EGFP.
Genotyping protocol and further details on gene targeting used can be found
in the Supplemental Experimental Procedures.
Animals, Radiograph, Tissue Preparation, and
Immunohistochemistry
All mouse experiments were performed in accordance with humane practices,
national and international regulations, and with the approval of the University
of Utah Institutional Animal Care and Use committee. Radiographs were
obtained postasphyxiation using a Carestream 4000 Pro-Fx instrument
(Carestream Molecular Imaging, Woodbridge, CT, USA).
Mouse tumors were extracted after asphyxiation and were fixed overnight in
4% paraformaldehyde prior to embedding in paraffin. Immunostaining and
tissue preparation along with antibodies used are described in the Supple-
mental Experimental Procedures.
Transcriptome Analysis
A portion of each tumor was snap frozen for delayed total RNA extraction using
the QIAGEN RNeasy Mini kit (QIAGEN, Valencia, CA, USA). RT-PCR was
performed with random hexamer primers to generate cDNAs, followed by
PCR for specific transcripts (Supplemental Experimental Procedures).
For RNA sequencing, total RNAwas prepared using an Illumina TruSeq RNA
sample prep kit (Illumina, San Diego, CA, USA) and quality checked with an
Agilent Bioanalyzer RNA 6000 chip (Agilent Technologies, Santa Clara, CA,
USA). mRNAs were captured by oligodT magnetic beads and fragmented.
Library quality was then checked by Nanodrop analysis (Thermo Scientific,
Wilmington, DE, USA), qPCR quantitation using Illumina primers, and another
bioanalyzer run. Sequencing was performed on an Illumina HiSeq 2000
machine (Illumina) using a 50-cycle single-end read. PhiX control library reads
were added to each lane for quality assurance. Reads were then aligned with
the mm9 mouse genome. Basic clusterings were performed using GeneSifter
software (Geospiza, Seattle, WA, USA). Methods used to classify tumor type
using RNA-seq data can be found in the Supplemental Experimental
Procedures.ancer Cell 23, 215–227, February 11, 2013 ª2013 Elsevier Inc. 225
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